Uromigos-ASCO GU

The UromigosThe Uromigos | February 19, 2022
Axel Bex, MD, PhD, from the Netherlands Cancer Institute, Amsterdam, described results of the NeoAvAx trial as ...
Read More
The UromigosThe Uromigos | February 19, 2022
Dr. Fred Saad describes the results of the PROpel Phase III trial.
The UromigosThe Uromigos | February 18, 2022
Dr. Jonathan Rosenberg describes the results of this positive randomized phase 2 trial.
The UromigosThe Uromigos | February 18, 2022
Dr Petros Grivas describes the results of this phase 2 trial.
The UromigosThe Uromigos | February 17, 2022
Kim Chi, MD, describes the results of the MAGNITUDE trial,
The UromigosThe Uromigos | February 17, 2022
Results from the ARASENS trial appear to have confirmed triple therapy as the new standard of care for mHSPC.
The UromigosThe Uromigos | February 10, 2022
Pete Nelson, MD, describes mechanism of action and current clinical application in prostate cancer.
Advertisement
Advertisement